Shen Mimi, Ma Zhiyuan, Zhu Jiaxing, Wen Guorong, Jin Hai, An Jiaxing, Tuo Biguang, Liu Xuemei, Li Taolang
Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China; Department of Thyroid and Breast Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Bioorg Chem. 2025 Jan;154:108095. doi: 10.1016/j.bioorg.2024.108095. Epub 2024 Dec 24.
Breast cancer is the most prevalent malignant tumour among women. Approximately 70 % of patients are hormone receptor (HR)-positive and undergo endocrine therapy as the main form of treatment; however, the efficacy of this type of therapy is limited by some factors, such as drug resistance and complex tumour microenvironments. Using network pharmacology and molecular docking, this study examined how CDK4/6 inhibitors enhance the effects of immunotherapy for HR-positive breast cancer, focusing on their effects on the tumour microenvironment (TME) and immune cell activity. CDK4/6 inhibitor influence crucial signalling pathways, including TP53 and EGFR, underscoring their importance in modulating immune responses and combating drug resistance. Our analysis revealed that the combination of CDK4/6 inhibitors with other immunotherapies, such as immune checkpoint inhibitors, might play an important role in improving the effectiveness of treatment in patients with cancer. This study provides new perspectives on treatment options for HR-positive breast cancers, promoting ongoing research and improvements in therapeutic approaches.
乳腺癌是女性中最常见的恶性肿瘤。大约70%的患者为激素受体（HR）阳性，并接受内分泌治疗作为主要治疗方式；然而，这类治疗的疗效受到一些因素的限制，如耐药性和复杂的肿瘤微环境。本研究利用网络药理学和分子对接技术，研究了CDK4/6抑制剂如何增强HR阳性乳腺癌免疫治疗的效果，重点关注其对肿瘤微环境（TME）和免疫细胞活性的影响。CDK4/6抑制剂影响关键信号通路，包括TP53和EGFR，突显了它们在调节免疫反应和对抗耐药性方面的重要性。我们的分析表明，CDK4/6抑制剂与其他免疫疗法（如免疫检查点抑制剂）联合使用，可能在提高癌症患者治疗效果方面发挥重要作用。本研究为HR阳性乳腺癌的治疗选择提供了新的视角，推动了正在进行的研究和治疗方法的改进。
